Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HVPG predicts clinical benefit after sustained virologic response

Key clinical point: For patients with hepatitis C virus infection who achieve sustained virologic response to interferon-free therapy, changes in hepatic venous pressure gradient predict clinical benefit.

Major finding: After 3 years, 40.1% of patients with posttherapy hepatic venous pressure gradient measurements of at least 16 mm Hg developed hepatic decompensation, an event that occurred in none of the patients with a posttherapy hepatic venous pressure gradient of 9 mm Hg or less.

Study details: An observational study involving 90 patients with hepatitis C virus infection who achieved sustained virologic response after interferon-free therapy.

Disclosures: The study was funded by the Medical Scientific Fund of the city of Vienna. The investigators disclosed relationships with AbbVie, Bristol-Myers Squibb, Gilead, and others.

Citation:

Mandorfer M et al. The Liver Meeting 2019, Abstract 146.